Advanced search
Publication Cover
Hematology Volume 29, 2024 - Issue 1
Submit an article Journal homepage
767
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Real-world long-term safety and effectiveness of turoctocog alfa in the treatment of haemophilia A in Japan: results from a multicentre, non-interventional, post-marketing study

Azusa Nagaoa Department of Blood Coagulation, Ogikubo Hospital, Tokyo, JapanView further author information
,
Ayumi Deguchib Medical Affairs, Novo Nordisk Pharma Ltd., Tokyo, JapanView further author information
&
Keiji Nogamic Department of Pediatrics, Nara Medical University, Kashihara, JapanCorrespondence[email protected]
View further author information
Article: 2316540 | Received 20 Apr 2023, Accepted 05 Feb 2024, Published online: 20 Feb 2024

References

  • Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1–158. doi: 10.1111/hae.14046
  • Ministry of Health, Labour and Welfare. Nationwide Survey on Blood Coagulation Disorders 2021 [in Japanese]. 2021. [Accessed 10 November 2022]. https://api-net.jfap.or.jp/image/data/blood/r03_research/r03_research.pdf
  • Mannucci PM. Hemophilia therapy: the future has begun. Haematologica. 2020;105(3):545–553. doi: 10.3324/haematol.2019.232132
  • Novo Nordisk. NOVOEIGHT (antihemophilic factor, recombinant) Package Insert. 2018. [Accessed 10 November 2022]. https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/novoeight.
  • Novo Nordisk. NovoEight® (Turoctocog Alfa) Japan Package Insert. 2019.
  • John MJ, Chakrabarti P, Apte S, et al. Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: guardian 10 trial results. Res Pract Thromb Haemost. 2020;4(8):1324–1330. doi: 10.1002/rth2.12441
  • Kulkarni R, Karim FA, Glamocanin S, et al. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics. Haemophilia. 2013;19(5):698–705. doi: 10.1111/hae.12165
  • Lentz SR, Janic D, Kavakli K, et al. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: final results from the guardian 2 extension trial. Haemophilia. 2018;24(6):e391–e394. doi: 10.1111/hae.13617
  • Lentz SR, Misgav M, Ozelo M, et al. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia. 2013;19(5):691–697. doi: 10.1111/hae.12159
  • Wu R, Sun J, Xu W, et al. Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeding episodes in previously treated patients from China with severe hemophilia A: results from the guardian 7 trial. Ther Clin Risk Manag. 2020;16:567–578. doi: 10.2147/TCRM.S243146
  • Yaish H, Matsushita T, Belhani M, et al. Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: results from the guardian 4 multinational clinical trial. Haemophilia. 2020;26(1):64–72. doi: 10.1111/hae.13883
  • Escuriola Ettingshausen C, Katsarou O, Kotnik BF, et al. Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII-treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study. Haemophilia. 2022;28(1):46–54. doi: 10.1111/hae.14454
  • Blonde L, Khunti K, Harris SB, et al. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763–1774. doi: 10.1007/s12325-018-0805-y
  • Ministry of Health, Labour and Welfare (MHLW). Article 14-4, Act on Securing of Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices “re-examination of new drugs”. 2005.
  • Ministry of Health, Labour and Welfare (MHLW). Ordinance No. 171 of 2004, Ministerial Ordinance on Good Post-marketing Study Practice for Drugs (GPSP). 2004.
  • Public Policy Committee, International Society of Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf. 2016;25(1):2–10. doi: 10.1002/pds.3891
  • Guidelines for the management of acquired hemophilia A development committee. Guidelines for the management of acquired hemophilia A: 2017 revision [in Japanese]. Japanese Journal of Thrombosis and Hemostasis. 2017;28(6):715–747. doi: 10.2491/jjsth.28.715
  • Yamazaki S, Taki M. Methodological issue of assay for inhibitors to factor VIII/IX [in Japanese]. Japanese Journal of Thrombosis and Hemostasis. 2010;21(5):484–488. doi: 10.2491/jjsth.21.484
  • Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol. 2013;4(1):59–72. doi: 10.1177/2040620712464509
  • Hassan S, Cannavò A, Gouw SC, et al. Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review. J Thromb Haemost. 2018;16(6):1055–1068. doi: 10.1111/jth.14124
  • Santagostino E, Lentz SR, Misgav M, et al. Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials. Haemophilia. 2015;21(1):34–40. doi: 10.1111/hae.12518
  • Pocoski J, Li N, Ayyagari R, et al. Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A. J Blood Med. 2016;7:129–137. doi: 10.2147/JBM.S104074

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.